St. John’s Wort

Based on a published clinical trial, Euromed has made available its UltraFlow® St. John’s Wort extract in the U.S. The new UltraFlow ingredient was tested and found safe and effective in a European clinical trial. In the 11,000-patient study published in Deutsche Apoteker Zeitung, a European pharmaceutical journal, subjects were given a 600 mg St. John’s Wort tablet once a day, using the UltraFlow formulation, which resulted in significant improvement in depressive symptoms with minimal side effects, according to the company. In addition, 83% of the physicians participating in the study noted significantly improved compliance with the once-a-day dosing and side effects were reported in less than 1% of patients.